InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 8 January 2024

This study is evaluating how safe and effective a new drug (called ISB 1442) is in people with relapsed or refractory multiple myelomaA Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Participants With Relapsed/Refractory Multiple Myeloma

Clinical summary

Summary

This study will be conducted in two phases.

Phase 1: Dose escalation in relapsed or refractory (R/R) multiple myeloma (MM). In this phase, participants with R/R MM will be administered ISB 1442 weekly by subcutaenous (SC) injection in each 28-day cycle. Participants will receive escalating doses.

Phase 2: Dose expansions in select R/R MM. This phase includes multiple cohorts based on specific disease type.

  • Cohort A: R/R MM participants who have received at least 3 prior lines of therapy. Participants will receive the Recommended Phase 2 Dose (RP2D) of ISB 1442 SC injection as determined in Phase 1 of the study.
  • Cohort B: R/R MM Post-T-cell-Directed Therapy. Participants will receive the RP2D of ISB 1442 as SC injection. 

Conditions

This trial is treating patients with multiple myeloma

Cancer

Blood Cancers Haematological

Age

People18+

Phase

I/II

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

Ichnos Sciences SA

Scientific Title

A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Participants With Relapsed/Refractory Multiple Myeloma

Eligibility

Inclusion

  1. Male or female patients aged 18 years or older.
  2. Be willing and able to provide written informed consent and any locally required authorization (eg, Health Insurance Portability and Accountability Act of 1996 [HIPAA]) prior to any protocol related procedures, including screening evaluations
  3. Phase 1: Patients with pathologically confirmed multiple myeloma (MM) who have progressed on or after standard therapy (relapsed/refractory [R/R] patients):

    1. Must have received at least 3 prior lines of therapy, including PIs, IMiDs, and anti CD38 therapies either in combination or as a single agent; and must not be candidates for regimens known to provide clinical benefit. (Note: Patients in Australia may have received any of the therapies including PIs, IMiDs, and anti CD38 therapies either in combination or as a single agent; and must not be candidates for regimens known to provide clinical benefit ).
    2. Must have measurable M-protein (serum and/or 24-hr urine, or serum free light chains).
  4. Phase 2: Patients with pathologically confirmed MM who have progressed on or after standard therapy (R/R patients):

    Cohort A: R/R MM

    1. Must have received at least 3 prior lines of therapy, including PIs, IMiDs, and anti CD38 therapies either in combination or as a single agent;
    2. Must have measurable disease defined by at least 1 of the following abnormalities (as per IMWG criteria):

      • Serum M-protein ≥ 0.5 g/L (IgA ≥ 0.5 g/L), or
      • Urine light-chain (M-protein) of ≥ 200 mg/24 hours, or
      • Serum free light chain (sFLC) assay: involved free light chain (FLC) level ≥ 10 mg/dL provided sFLC ratio is abnormal.

    Cohort B: R/R MM Post-T-Cell Directed Therapy

    1. Must have received at least 3 prior lines of therapy, including PIs, IMiDs and anti-CD38 therapies either in combination or as a single agent; and have relapsed and/or be refractory to a T-cell directed therapy including cellular therapies or T cell engagers.
    2. Must have measurable disease defined by at least 1 of the following abnormalities (as per IMWG criteria):

      • Serum M-protein ≥ 0.5 g/L (IgA ≥ 0.5 g/L), or
      • Urine light-chain (M-protein) of ≥ 200 mg/24 hours, or
      • sFLC assay: involved FLC level ≥ 10 mg/dL provided sFLC ratio is abnormal
  5. Have a body weight ≥ 40.0 kg at screening.
  6. Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less.
  7. Have life expectancy of at least 3 months (from date of informed consent signing).
  8. Have adequate organ function, including:

    1. Aspartate aminotransferase (AST, GOT) and alanine aminotransferase (ALT, GPT) ≤3.0 × ULN; bilirubin ≤1.5 × ULN. Patients with Gilbert's syndrome may have a bilirubin level >1.5 × ULN, per discussion between the Investigator and medical monitor.
    2. Estimated creatinine clearance ≥45 mL/min as calculated using the Cockcroft-Gault formula or 24-hour urine collection.
  9. Left ventricular ejection fraction (LVEF) ≥45% as assessed by echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan.

Exclusion

  1. Participants with relapsed disease where relapse is characterized only by minimal residual disease parameters (i.e., minimal residual disease positive).
  2. Participants with MM with disease where the only measurable parameter is plasmacytoma.
  3. Received treatment with anti-CD38 antibodies or CD47 targeted therapies within 1 month of C1D1; systemic anticancer treatments within 14 days before the first dose of study drug (C1D1) or any investigational products within 5 half-lives of C1D1, whichever is appropriate to last therapy received. (eg, non-IMP IMiD, proteasome inhibitor could be considered to be eligible if there is at least 14 days after last dose before C1D1. Note: Treatment with a single course of glucocorticoids is allowed (maximum dose of corticosteroids should not exceed the equivalent of 160 mg [for example, 40 mg/d for 4 days] of dexamethasone). Hormonal therapy for prostate cancer or breast cancer (as adjuvant treatment), and treatment with bisphosphonates and receptor activator of nuclear factor kappa-Β ligand inhibitors are allowed.
  4. Received autologous stem cell transplantation within 12 weeks of C1D1.
  5. Current participation in another interventional study, including other clinical trials with investigational agents (including investigational vaccines or investigational medical device for disease under study) within 4 weeks of C1D1 and throughout the duration of this trial.
  6. Prior radiation therapy within 14 days of C1D1; or prior irradiation to > 25% of the bone marrow. Note: Prophylactic localized ("spot") radiation for areas of pain is allowed.
  7. Active malignant central nervous system involvement
  8. Known to be refractory to platelet or RBC transfusions
  9. Known severe allergic or anaphylactic reactions to human recombinant proteins or excipients used in the ISB 1442 formulation.
  10. QTc interval > 480 msec at screening using Fredericia's QT correction formula.

Inclusion

  • You have had a certain type of treatment or surgical procedure.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

Exclusion

  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.